Guy Malchi has joined Rosetta Genomics in the newly created position of Executive Vice President of Corporate Development. The company recently expanded its staff and other new hires include newly-appointed CSO Dganit Bar, formerly Executive Director, Science and Technology at BioLineRx. At Rosetta Malchi will focus on leading the Company’s...
Read more
Blog
Regulatory Compliance Course Nov.29-Dec.27
A course on Regulatory Strategies and Compliance in the Development of Drugs & Biotechnology-Derived Products will be held at the Leonardo City Tower, 14 Zisman Street ,Ramat-Gan on 29 November, 06, 20 and 27 December 2012. The instructor is Dr. Moshe Neuman, PhD, CEO & President of B.R.D.– Bio Medical...
Read more
Daniel Chain Sues Pfizer for $2M
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology. Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure...
Read more
Steba Prostate Cancer in Phase 3
Very few Israeli technologies reach the Phase 3 clinical stage, yet a therapy for prostate cancer, invented and developed in Rehovot, has quietly worked its way to this elite club. The technology, known as Tookad-WS, was invented at the Weizmann Institute by Prof. Avigdor Scherz and Prof. Yoram Salomon. The...
Read more
New Reasons for Doing Clinical Research in the UK: Nov.7-8 in Ramat Gan
“Israeli companies that have overlooked the UK as a trial site, now can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and in the UK by a new agency, NOCRI, the NIHR Organization for Clinical Research Infrastructure in the UK,” says Iris...
Read more